Join Sharesand AJ Bell for an evening of investment inspiration and get to meet the decision makers behind some of the UK’s fastest growing listed companies.
The event on 10 July 2018 in London will include:
•Presentations from Directors of MaxCyte and Mereo BioPharma + more companies to be announced
•An opportunity for you to talk directly with the Directors and ask your questions about the company’s core strengths and their short & long term business strategy
•Meet fellow investors and share your investing experience
•Complimentary drinks and food
More about the companies presenting:
Destiny Pharma (DEST) is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.The proprietary, new antimicrobial drug platform at Destiny Pharma, the XF Drug Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response.
MaxCyte (MXCT) is a US-based global company driving the acceleration of the discovery, development, manufacturing and commercialization of next-generation, cell-based medicines. The Company provides its patented, high-performance cell engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing, and cell therapy, including gene editing and immuno-oncology.
Mereo BioPharma Group (MPH) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for patients with rare diseases with its two lead programs targeting Brittle Bone Disease (or Osteogenesis Imperfecta) and the respiratory disease Alpha-1 Antitrypsin Deficiency.
Wishbone Gold (WSBN) is an AIM listed company operating in the precious metals market through two strategies. It has a wholly owned precious metals trading business centred in Dubai, United Arab Emirates. The Company also holds four exploration licences in North East Queensland, Australia, in an area covering over 34,000 acres known for significant precious metal mineralisation.
Who Should Attend
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Registration and coffee
Neil Clark, CEO - Destiny Pharma (DEST)
Doug Doerfler, President & Chief Executive Officer - MaxCyte (MXCT)
Richard Jones, Chief Financial Officer - Mereo BioPharma Group (MPH)